Staar Surgical Co.

STAA

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0000718937

B

second fifth of 305 graded peers in healthcare

rank 100 of 305; percentile 32.6; sampling error 2.8 points; lower is stronger

A B C D E

B, the elk



Scoreboard	
Profitability	C percentile 50.8
Solvency	B percentile 31.2
Growth and financing	C percentile 44.7
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $451.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	8 of 13
Graded from	filings received through Mar 3, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$26.02 2026-11-16; market equity $1.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or "refractive" surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 50.8						
Gross profitability	40.4%	32.8%		32.5	346	2026-01-02
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(9.6%)	(6.7%)	42.1	756	2026-01-02
Gross margin stability, five years	6.5 pts	2.8 pts	78.0	237	2026-01-02
Solvency, sleeve percentile 31.2					
Altman Z double-prime	4.46	0.31	21.2	705	2026-01-02
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2017-12-29; latest annual assets end 2026-01-02					
Current ratio	4.55x	2.68x	41.2	781	2026-01-02
Growth and financing, sleeve percentile 44.7					
Revenue growth, three-year compound	0.0%	9.6%	71.2	400	2026-01-02
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	2.5%	3.2%	46.1	663	2026-01-02
Net share issuance, one year	0.4%	1.6%	16.9	624	2026-02-27

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
95	Twist Bioscience Corp. (TWST)	30.9	B	fortress balance sheet
96	Steris plc (STE)	31.2	B	
97	BioNexus Gene Lab Corp. (BGLC)	31.6	B	dilution, late filer
98	Sarepta Therapeutics, Inc. (SRPT)	31.9	B	
99	Amphastar Pharmaceuticals, Inc. (AMPH)	32.2	B	
100	Staar Surgical Co. (STAA)	32.6	B	
101	Arcutis Biotherapeutics, Inc. (ARQT)	32.9	B	
102	Stryker Corp. (SYK)	33.2	B	
103	Usana Health Sciences Inc. (USNA)	33.6	B	
104	Collegium Pharmaceutical, Inc. (COLL)	33.9	B	fortress balance sheet
105	Puma Biotechnology, Inc. (PBYI)	34.2	B	fortress balance sheet

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(12.6%)	(1.7%)	41
Distance from 52-week high	(22.0%)	(31.5%)	57
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(3.1%)	0.5%	36
Book value to price	0.29	0.28	51
Sales to price	0.18	0.36	30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	7.5%	13.2%	42
Relative strength against the sector, log excess return	(0.31)	(0.19)	41
Twelve-month failure probability, CHS model	0.03%	0.06%	25

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-01-02	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$133.6M
Operating cash flow, four quarters	$21.4M
Months of runway	not finite
Days since last periodic filing	13 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$16.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$182.4M	2026-01-02	2026-03-03	10-K	26-000004
2	assets	us-gaap:Assets	$451.7M	2026-01-02	2026-03-03	10-K	26-000004
3	net income	us-gaap:NetIncomeLoss	-$80.4M	2026-01-02	2026-03-03	10-K	26-000004
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$34.2M	2026-01-02	2026-03-03	10-K	26-000004
5	assets	us-gaap:Assets	$509.5M	2024-12-27	2026-03-03	10-K	26-000004
6	revenue	us-gaap:Revenues	$239.4M	2026-01-02	2026-03-03	10-K	26-000004
7	gross profit	us-gaap:GrossProfit	$239.6M	2024-12-27	2026-03-03	10-K	26-000004
8	revenue	us-gaap:Revenues	$313.9M	2024-12-27	2026-03-03	10-K	26-000004
9	gross profit	us-gaap:GrossProfit	$252.7M	2023-12-29	2026-03-03	10-K	26-000004
10	revenue	us-gaap:Revenues	$322.4M	2023-12-29	2026-03-03	10-K	26-000004
11	gross profit	us-gaap:GrossProfit	$223.4M	2022-12-30	2025-02-21	10-K	25-024813
12	revenue	us-gaap:Revenues	$239.4M	2022-12-30	2026-03-03	10-K	26-000004
13	gross profit	us-gaap:GrossProfit	$178.6M	2021-12-31	2024-02-27	10-K	24-020572
14	revenue	us-gaap:Revenues	$230.5M	2021-12-31	2024-02-27	10-K	24-020572
15	current assets	us-gaap:AssetsCurrent	$311.5M	2026-01-02	2026-03-03	10-K	26-000004
16	current liabilities	us-gaap:LiabilitiesCurrent	$68.5M	2026-01-02	2026-03-03	10-K	26-000004
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$148.0M	2026-01-02	2026-03-03	10-K	26-000004
18	operating income	us-gaap:OperatingIncomeLoss	-$91.7M	2026-01-02	2026-03-03	10-K	26-000004
19	book equity	us-gaap:StockholdersEquity	$344.2M	2026-01-02	2026-03-03	10-K	26-000004
20	liabilities	us-gaap:Liabilities	$107.5M	2026-01-02	2026-03-03	10-K	26-000004
21	operating income	us-gaap:OperatingIncomeLoss	-$3.6M	2017-12-29	2020-02-26	10-K	20-006791
22	interest expense	us-gaap:InterestExpense	$112,000	2017-12-29	2018-02-28	10-K	18-011838
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.8M	2026-01-02	2026-03-03	10-K	26-000004
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$15.7M	2024-12-27	2026-03-03	10-K	26-000004
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$23.4M	2024-12-27	2026-03-03	10-K	26-000004
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$14.6M	2023-12-29	2026-03-03	10-K	26-000004
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$18.2M	2023-12-29	2026-03-03	10-K	26-000004

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$35.7M	2022-12-30	2025-02-21	10-K	25-024813
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$18.1M	2022-12-30	2025-02-21	10-K	25-024813
30	depreciation amortization	us-gaap:Depreciation	$8.3M	2026-01-02	2026-03-03	10-K	26-000004
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$82.3M	2026-01-02	2026-03-03	10-K	26-000004
32	income tax	us-gaap:IncomeTaxExpenseBenefit	-$1.8M	2026-01-02	2026-03-03	10-K	26-000004
33	current assets	us-gaap:AssetsCurrent	$367.9M	2024-12-27	2026-03-03	10-K	26-000004
34	current liabilities	us-gaap:LiabilitiesCurrent	$70.3M	2024-12-27	2026-03-03	10-K	26-000004
35	assets	us-gaap:Assets	$488.7M	2023-12-29	2025-02-21	10-K	25-024813
36	assets	us-gaap:Assets	$418.8M	2022-12-30	2024-02-27	10-K	24-020572
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,512,749	2026-02-27	2026-03-03	10-K	26-000004
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,325,372	2025-02-18	2025-02-21	10-K	25-024813

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.